*ASCRS Disclaimer: All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve, or recommend the use of any products, devices, or services. Randomized, Multicenter, 12-Month Evaluation of Effectiveness and Safety of the Gel Stent Vs Trabeculectomy: The Gold Standard Pathway Studyġ2-Month Outcomes Of Ab-Externo Gel Stent Placement In Eyes Naïve Vs Not Naïve To Conjunctival-Incisional Glaucoma Surgery: The EXPAND Study
Session: Presbyopia Correction: New Treatments and Studies GEMINI 1 & 2 Pooled Phase 3: The Evaluation of Intermediate Vision for Presbyopia Patients Treated with AGN-190584ĪGN-190584 Improves Photopic Distance Corrected Near Vision in Participants with Mild to Moderate Presbyopia: Results of the Phase 3 StudiesĪGN-190584 Improves Near and Intermediate Vision in a Subgroup of Subjects with Moderate to Advanced Presbyopia Session: Presbyopia Correction – Outcomes/ComparisonsĪGN-190584 and Rapid Visual Acuity Improvement in Presbyopia on Day 1 of Treatment: Results from the Phase 3 Studies GEMINI 1 & 2 Pooled Phase 3: The Proportion of Subjects with Clinically Meaningful Near Vision Improvement ĭetails about Allergan's presentations are as follows: The XEN ® Gel Stent is FDA-cleared for insertion via an ab interno approach ab externo insertion of XEN ® Gel Stent is investigational and the safety and efficacy of this approach have not been evaluated by the FDA.Ī complete listing of the Allergan ASCRS 2022 Annual Meeting abstracts can be viewed at. The XEN ® Glaucoma Treatment System is indicated for the surgical management of refractory glaucoma, including cases where previous surgical treatment has failed cases of primary open angle glaucoma and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy. AbbVie will also present an analysis evaluating intermediate vision for presbyopia patients treated with VUITY.Īdditionally, new analyses from studies assessing the safety and efficacy of the XEN ® Gel Stent will be presented. Notable data will include a post-hoc analysis evaluating the use of VUITY in participants with moderate to advanced presbyopia and a new analysis evaluating the onset of efficacy in participants with presbyopia. Robinson, M.D., vice president, global therapeutic area head, ophthalmology, AbbVie.Īt the meeting, researchers will present new studies on the safety and efficacy of VUITY in a variety of settings. "The data we'll be presenting at ASCRS showcases our continued commitment to innovate and provide additional treatment options for patients with eye conditions like presbyopia and glaucoma," said Michael R. Presentations will include new data on VUITY TM (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults and XEN ® Gel Stent, a surgical implant designed to lower high eye pressure, FDA-cleared for refractory glaucoma patients. NORTH CHICAGO, Ill., Ap/PRNewswire/ - Allergan, an AbbVie (NYSE: ABBV) company, announced that it will present new data from its leading eye care portfolio at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22 – 26 in Washington, D.C. Seven abstract presentations reinforce leadership in eye care, including continued presbyopia and glaucoma treatment research
0 kommentar(er)
